Human Placenta-Derived Adherent Cells Prevent Bone loss, Stimulate Bone formation, and Suppress Growth of Multiple Myeloma in Bone
Open accessThe DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Abstract
Human placenta has emerged as a valuable source of transplantable cells of mesenchymal and hematopoietic origin for multiple cytotherapeutic purposes, including enhanced engraftment of hematopoietic stem cells, modulation of inflammation, bone repair, and cancer. Placenta-derived adherent cells (PDACs) are mesenchymal-like stem cells isolated from postpartum human placenta. Multiple myeloma is closely associated with induction of bone disease and large lytic lesions, which are often not repaired and are usually the sites of relapses. We evaluated the antimyeloma therapeutic potential, in vivo survival, and trafficking of PDACs in the severe combined immunodeficiency (SCID)–rab model of medullary myeloma-associated bone loss. Intrabone injection of PDACs into nonmyelomatous and myelomatous implanted bone in SCID-rab mice promoted bone formation by stimulating endogenous osteoblastogenesis, and most PDACs disappeared from bone within 4 weeks. PDACs inhibitory effects on myeloma bone disease and tumor growth were dose-dependent and comparable with those of fetal human mesenchymal stem cells (MSCs). Intrabone, but not subcutaneous, engraftment of PDACs inhibited bone disease and tumor growth in SCID-rab mice. Intratumor injection of PDACs had no effect on subcutaneous growth of myeloma cells. A small number of intravenously injected PDACs trafficked into myelomatous bone. Myeloma cell growth rate in vitro was lower in coculture with PDACs than with MSCs from human fetal bone or myeloma patients. PDACs also promoted apoptosis in osteoclast precursors and inhibited their differentiation. This study suggests that altering the bone marrow microenvironment with PDAC cytotherapy attenuates growth of myeloma and that PDAC cytotherapy is a promising therapeutic approach for myeloma osteolysis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Human mesenchymal stem cells exert potent antitumorigenic effects in a model of Kaposi's sarcoma
Khakoo, A. Y., Pati, S., Anderson, S. A., Reid, W., Elshal, M. F., Rovira, I. I., Nguyen, A. T., Malide, D., Combs, C. A., Hall, G., et al. (2006) · The Journal of Experimental Medicine · doi:10.1084/jem.20051921 · Cited by 747
Bone marrow mesenchymal stem cells are abnormal in multiple myeloma
Corre, J., Mahtouk, K., Attal, M., Gadelorge, M., Huynh, A., Fleury-Cappellesso, S., Danho, C., Laharrague, P., Klein, B., Rème, T., et al. (2007) · Leukemia · doi:10.1038/sj.leu.2404621 · Cited by 328
Yaccoby, S., Pearse, R. N., Johnson, C. L., Barlogie, B., Choi, Y., & Epstein, J. (2002) · British Journal of Haematology · doi:10.1046/j.1365-2141.2002.03257.x · Cited by 305
Self-citationMultiple myeloma bone disease: pathophysiology of osteoblast inhibition
Giuliani, N., Rizzoli, V., & Roodman, G. D. (2006) · Blood · doi:10.1182/blood-2006-05-026112 · Cited by 302
Standal, T., Abildgaard, N., Fagerli, U.-M., Stordal, B., Hjertner, Ø., Borset, M., & Sundan, A. (2007) · Blood · doi:10.1182/blood-2006-07-034884 · Cited by 167
Garayoa, M., Garcia, J. L., Santamaria, C., Garcia-Gomez, A., Blanco, J. F., Pandiella, A., Hernández, J. M., Sanchez-Guijo, F. M., del Cañizo, M.-C., Gutiérrez, N. C., et al. (2009) · Leukemia · doi:10.1038/leu.2009.65 · Cited by 148
The (in) auspicious role of mesenchymal stromal cells in cancer: be it friend or foe
Kidd, S., Spaeth, E., Klopp, A., Andreeff, M., Hall, B., & Marini, F. (2008) · Cytotherapy · doi:10.1080/14653240802486517 · Cited by 128 · cited 2×
“Despite a safety concern that mesenchymal cells, rich with cytokines and chemokines, may stimulate tumor growth [42], our findings revealed that growth rates of myeloma cell lines were lower when cocultured with PDACs than with MSCs from fetal bone or MM patients.”
Research works printed but not linked: 40
- Walker, 2007, Magnetic resonance imaging in multiple myeloma: Diagnostic and clinical implications, J Clin Oncol, 25, 1121, 10.1200/JCO.2006.08.5803 · DOI · Paper page
- Bartel, 2009, F18-fluorodeoxyglucose positron emission tomography in the context of other imaging techniques and prognostic factors in multiple myeloma, Blood, 114, 2068, 10.1182/blood-2009-03-213280 · DOI · Paper page
- Berenson, 1996, Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma. Myeloma Aredia Study Group, N Engl J Med, 334, 488, 10.1056/NEJM199602223340802 · DOI · Paper page
- Zangari, 2005, Response to bortezomib is associated to osteoblastic activation in patients with multiple myeloma, Br J Haematol, 131, 71, 10.1111/j.1365-2141.2005.05733.x · DOI · Paper page
- Pennisi, 2009, The proteasome inhibitor, bortezomib suppresses primary myeloma and stimulates bone formation in myelomatous and nonmyelomatous bones in vivo, Am J Hematol, 84, 6, 10.1002/ajh.21310 · DOI
- Breitkreutz, 2008, Lenalidomide inhibits osteoclastogenesis, survival factors and bone-remodeling markers in multiple myeloma, Leukemia, 22, 1925, 10.1038/leu.2008.174 · DOI · Paper page
- Stewart, 2006, Role of osteoblast suppression in multiple myeloma, J Cell Biochem, 98, 1, 10.1002/jcb.20774 · DOI
- Yaccoby, 2007, Antibody-based inhibition of DKK1 suppresses tumor-induced bone resorption and multiple myeloma growth in vivo, Blood, 109, 2106, 10.1182/blood-2006-09-047712 · DOI · Paper page
- Tian, 2003, The role of the Wnt-signaling antagonist DKK1 in the development of osteolytic lesions in multiple myeloma, N Engl J Med, 349, 2483, 10.1056/NEJMoa030847 · DOI · Paper page
- Oshima, 2005, Myeloma cells suppress bone formation by secreting a soluble Wnt inhibitor, sFRP-2, Blood, 106, 3160, 10.1182/blood-2004-12-4940 · DOI · Paper page
- Ehrlich, 2005, IL-3 is a potential inhibitor of osteoblast differentiation in multiple myeloma, Blood, 106, 1407, 10.1182/blood-2005-03-1080 · DOI · Paper page
- Giuliani, 2005, Myeloma cells block RUNX2/CBFA1 activity in human bone marrow osteoblast progenitors and inhibit osteoblast formation and differentiation, Blood, 106, 2472, 10.1182/blood-2004-12-4986 · DOI · Paper page
- Bataille, 1991, Recruitment of new osteoblasts and osteoclasts is the earliest critical event in the pathogenesis of human multiple myeloma, J Clin Invest, 88, 62, 10.1172/JCI115305 · DOI · Paper page
- Wallace, 2001, Abnormalities of bone marrow mesenchymal cells in multiple myeloma patients, Cancer, 91, 1219, 10.1002/1097-0142(20010401)91:7<1219::AID-CNCR1122>3.0.CO;2-1 · DOI · Paper page
- Mitsiades, 2007, The role of the bone marrow microenvironment in the pathophysiology of myeloma and its significance in the development of more effective therapies, Hematol Oncol Clin North Am, 21, 1007, 10.1016/j.hoc.2007.08.007 · DOI
- Prockop, 2007, Clinical trials with adult stem/progenitor cells for tissue repair: Let's not overlook some essential precautions, Blood, 109, 3147, 10.1182/blood-2006-03-013433 · DOI · Paper page
- Pittenger, 1999, Multilineage potential of adult human mesenchymal stem cells, Science, 284, 143, 10.1126/science.284.5411.143 · DOI · Paper page
- Uccelli, 2008, Mesenchymal stem cells in health and disease, Nat Rev Immunol, 8, 726, 10.1038/nri2395 · DOI · Paper page
- Prockop, 2007, “Stemness” does not explain the repair of many tissues by mesenchymal stem/multipotent stromal cells (MSCs), Clin Pharmacol Ther, 82, 241, 10.1038/sj.clpt.6100313 · DOI · Paper page
- Horwitz, 1999, Transplantability and therapeutic effects of bone marrow-derived mesenchymal cells in children with osteogenesis imperfecta, Nat Med, 5, 309, 10.1038/6529 · DOI · Paper page
- Parolini, 2008, Concise review: Isolation and characterization of cells from human term placenta: Outcome of the first international Workshop on Placenta Derived Stem Cells, Stem Cells, 26, 300, 10.1634/stemcells.2007-0594 · DOI · Paper page
- Prather, 2008, Placental-derived and expanded mesenchymal stromal cells (PLX-I) to enhance the engraftment of hematopoietic stem cells derived from umbilical cord blood, Expert Opin Biol Ther, 8, 1241, 10.1517/14712598.8.8.1241 · DOI
- Yata, 2004, The SCID-rab model: A novel in vivo system for primary human myeloma demonstrating growth of CD138-expressing malignant cells, Leukemia, 18, 1891, 10.1038/sj.leu.2403513 · DOI
- Yen, 2005, Isolation of multipotent cells from human term placenta, Stem Cells, 23, 3, 10.1634/stemcells.2004-0098 · DOI · Paper page
- Barlow, 2008, Comparison of human placenta- and bone marrow-derived multipotent mesenchymal stem cells, Stem Cells Dev, 17, 1095, 10.1089/scd.2007.0154 · DOI · Paper page
- Fukuchi, 2004, Human placenta-derived cells have mesenchymal stem/progenitor cell potential, Stem Cells, 22, 649, 10.1634/stemcells.22-5-649 · DOI · Paper page
- Shaughnessy, 2007, A validated gene expression model of high-risk multiple myeloma is defined by deregulated expression of genes mapping to chromosome 1, Blood, 109, 2276, 10.1182/blood-2006-07-038430 · DOI · Paper page
- Zhan, 2006, The molecular classification of multiple myeloma, Blood, 108, 2020, 10.1182/blood-2005-11-013458 · DOI · Paper page
- Li, 2007, Establishment and exploitation of hyperdiploid and non-hyperdiploid human myeloma cell lines, Br J Haematol, 138, 802, 10.1111/j.1365-2141.2007.06742.x · DOI
- Yaccoby, 2006, Inhibitory effects of osteoblasts and increased bone formation on myeloma in novel culture systems and a myelomatous mouse model, Haematologica, 91, 192
- Yaccoby, 1998, Primary myeloma cells growing in SCID-hu mice: A model for studying the biology and treatment of myeloma and its manifestations, Blood, 92, 2908, 10.1182/blood.V92.8.2908 · DOI · Paper page
- Yaccoby, 1999, The proliferative potential of myeloma plasma cells manifest in the SCID-hu host, Blood, 94, 3576, 10.1182/blood.V94.10.3576.422k01_3576_3582 · DOI · Paper page
- Yaccoby, 2004, Cancer and the microenvironment: Myeloma-osteoclast interactions as a model, Cancer Res, 64, 2016, 10.1158/0008-5472.CAN-03-1131 · DOI · Paper page
- Qiang, 2008, Wnt3a signaling within bone inhibits multiple myeloma bone disease and tumor growth, Blood, 112, 374, 10.1182/blood-2007-10-120253 · DOI · Paper page
- Prockop, 2009, Repair of tissues by adult stem/progenitor cells (MSCs): Controversies, myths, and changing paradigms, Mol Ther, 17, 939, 10.1038/mt.2009.62 · DOI · Paper page
- Caligaris-Cappio, 1991, Role of bone marrow stromal cells in the growth of human multiple myeloma, Blood, 77, 2688, 10.1182/blood.V77.12.2688.2688 · DOI · Paper page
- Pennisi, 2009, The ephrinB2/EphB4 axis is dysregulated in osteoprogenitors from myeloma patients and its activation affects myeloma bone disease and tumor growth, Blood, 114, 1803, 10.1182/blood-2009-01-201954 · DOI · Paper page
- Edwards, 2008, Increasing Wnt signaling in the bone marrow microenvironment inhibits the development of myeloma bone disease and reduces tumor burden in bone in vivo, Blood, 111, 2833, 10.1182/blood-2007-03-077685 · DOI · Paper page
- Yaccoby, 2010, Advances in the understanding of myeloma bone disease and tumour growth, Br J Haematol, 149, 311, 10.1111/j.1365-2141.2010.08141.x · DOI · Paper page
- Kidd, 2009, Direct evidence of mesenchymal stem cell tropism for tumor and wounding microenvironments using in vivo bioluminescent imaging, Stem Cells, 27, 2614, 10.1002/stem.187 · DOI · Paper page
Cited by
Prestwich, G. D. (2011) · Journal of Controlled Release · doi:10.1016/j.jconrel.2011.04.007 · Cited by 413
Mesenchymal stem cell secretome and regenerative therapy after cancer
Zimmerlin, L., Park, T. S., Zambidis, E. T., Donnenberg, V. S., & Donnenberg, A. D. (2013) · Biochimie · doi:10.1016/j.biochi.2013.05.010 · Cited by 168
“Intrabone and systemic delivery of MSC has been tested in a multiple myeloma animal model for simultaneous inhibition of tumor growth and regeneration of bone lesions [26].”
BackgroundReprogrammed marrow adipocytes contribute to myeloma-induced bone disease
Liu, H., He, J., Koh, S. P., Zhong, Y., Liu, Z., Wang, Z., Zhang, Y., Li, Z., Tam, B. T., Lin, P., et al. (2019) · Science Translational Medicine · doi:10.1126/scitranslmed.aau9087 · Cited by 113
Xu, S., Menu, E., Becker, A. D., Van Camp, B., Vanderkerken, K., & Van Riet, I. (2012) · Stem Cells · doi:10.1002/stem.787 · Cited by 103
Neuroprotective Effect of Human Placenta-Derived Cell Treatment of Stroke in Rats
Chen, J., Shehadah, A., Pal, A., Zacharek, A., Cui, X., Cui, Y., Roberts, C., Lu, M., Zeitlin, A., Hariri, R., et al. (2013) · Cell Transplantation · doi:10.3727/096368911x637380 · Cited by 70
“PDA001 cells are culture-expanded, undifferentiated cells with nominal phenotype CD34-, CD10, CD200, and CD105 (24).”
BackgroundInfluentialSelf-citation
Metadata
- Authors
- Li, X., Ling, W., Pennisi, A., Wang, Y., Khan, S., Heidaran, M., Pal, A., Zhang, X., He, S., Zeitlin, A., Abbot, S., Faleck, H., Hariri, R., Shaughnessy, J. D., van Rhee, F., Nair, B., Barlogie, B., Epstein, J., & Yaccoby, S.
- Venue
- Stem Cells
- Publisher
- Oxford University Press (OUP)
- Published
- 2011-02-01
- Volume
- 29
- Issue
- 2
- Pages
- 263-273
- ISSN
- 1066-5099 (ISSN-L)
- 1549-4918
- OpenAlex
- W2074379284
- Cited by
- 83
- References
- 7
- FWCI
- 3.37
- Type
- journal article
- Language
- en
- Open access
- bronze
- Licence
- academic.oup.com/journals/pages/open_access/funder_policies/chorus/standard_publication_model (vor)
- Funders
- Celgene Cellular Therapeutics (CA-093897)
- National Cancer Institute (CA55819, CA113992)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.